Oral cyclophosphamide for lupus glomerulonephritis: An underused therapeutic option

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 11, 2009, Pages 1754-1760

  McKinley, Alison ^a   Park, Edward ^a   Spetie, Dan ^a   Hackshaw, Kevin V ^a   Nagaraja, Smitha ^a   Hebert, Lee A ^a   Rovin, Brad H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AFRICAN AMERICAN; AGED; AMENORRHEA; ANEMIA; ANOREXIA; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PATIENT COMPLIANCE; PNEUMONIA; PROTEINURIA; RACE DIFFERENCE; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTEINURIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 73449094180     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02670409     Document Type: Article

References (27)

1. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, ALMS Investigators: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
2. Bargman JM: How did cyclophosphamide become the drug of choice for lupus nephritis? Nephrol Dial Transplant 24: 381-384, 2009
3. Austin HA, Klippel JH, Balow JE, le Riche WG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614-619, 1986
4. Wilson EC, Jayne DR, Dellow E, Fordham RJ: The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 46: 1096-1101, 2007
5. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D: Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61: 1495-1501, 2002
6. Dooley MA, Hogan S, Jennette JC, Falk R: Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Kidney Int 51: 1188-1195, 1997
7. Hebert LA: Management of lupus nephropathy. Nephron Clin Pract 93: C7-C12, 2003
8. Pendse S, Ginsburg E, Singh AK: Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis 43: 772-781, 2004
9. Sommers EC, Marder W, Christman GM, Ognenovski V, McCune J: Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52: 2761-2767, 2005
10. Chan TM, Tse KC, Tang CS, Lai KN, Li FK: Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14: 265-272, 2005
11. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Rovin BH: Renoprotection: One or many therapies. Kidney Int 59: 1211-1226, 2001
12. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA: Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 14: 3217-3232, 2003
13. Spetie DN, Tang Y, Rovin BH, Nadasdy G, Nadasdy T, Pesavento TE, Hebert LA: Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66: 2411-2415, 2004
14. Kasitanon N, Petri M, Haas M, Magder LS, Fine DM: Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: A retrospective study of 29 cases. Lupus 17: 40-45, 2008
15. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu C-Y, Nagaraja HN: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467-473, 2005
16. Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM, Lupus Nephritis Collaborative Study group: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326: 1373-1379, 1992
17. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46: 1003-1013, 2002
18. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC: Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38: 256-264, 2001
19. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343: 1156-1162, 2000
20. Chan TM, Tse KC, Tang CS, Mok M-Y, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076-1084, 2005
21. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon JP, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219-2228, 2005
22. Bao H, Liu Z-H, Xie H-L, Hu W-X, Zhang H-T, Li L-S: Successful treatment of class V-IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 19: 2001-2010, 2008
23. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D: Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980, 2004
24. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos M: Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57: 258-264, 2000
25. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
26. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis January 20, 2009 [epub ahead of print]
27. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati VD, Salmon J, Radhakrishnan J: Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 18: 2039-3046, 2003